TY  - JOUR
AU  - Goicoechea, Marian
AU  - Gomez-Preciado, Francisco
AU  - Benito, Silvia
AU  - Torras, Joan
AU  - Torra, Roser
AU  - Huerta, Ana
AU  - Restrepo, Alejandra
AU  - Ugalde, Jessica
AU  - Estefania Astudillo, Daniela
AU  - Agraz, Irene
AU  - Lopez-Mendoza, Manuel
AU  - de Arriba, Gabriel
AU  - Corchete, Elena
AU  - Quiroga, Borja
AU  - Jose Gutierrez, Maria
AU  - Luisa Martin-Conde, Maria
AU  - Lopes, Vanessa
AU  - Ramos, Carmela
AU  - Mendez, Irene
AU  - Cao, Mercedes
AU  - Dominguez, Fernando
AU  - Ortiz, Alberto
PY  - 2021
DO  - 10.1016/j.nefro.2021.01.002
SN  - 0211-6995
UR  - https://hdl.handle.net/10668/27447
T2  - Nefrologia
AB  - Fabry disease may be treated by enzyme replacement therapy (ERT), but the impact of chronic kidney disease (CKD) on the response to therapy remains unclear. The aim of the present study was to analyse the incidence and predictors of clinical events in...
LA  - en
PB  - Soc espanola nefrologia dr rafael matesanz
KW  - Fabry disease
KW  - Chronic kidney disease Enzyme replacement therapy
KW  - Renal events
KW  - Natural-history data
KW  - Agalsidase beta
KW  - Renal-disease
KW  - Lyso-gb3
KW  - Events
TI  - Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy
TY  - research article
VL  - 41
ER  -